Mitochondrial Renewal

The Mitochondrial Renewal stack targets the organelles responsible for 90% of cellular energy production — mitochondria — whose dysfunction is now recognized as a central driver of aging and age-related disease. SS-31 (Elamipretide, also known as Bendavia) is a cell-penetrating tetrapeptide that concentrates 1000-5000x in the inner mitochondrial membrane, where it binds cardiolipin. Cardiolipin is essential for electron transport chain complex organization, and its oxidation with age leads to respiratory chain inefficiency, ROS overproduction, and energy failure. SS-31 stabilizes cardiolipin, restoring electron transport efficiency and reducing oxidative damage at its source. It has completed Phase 3 trials for Barth syndrome and Phase 2 for heart failure. MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome''s 12S rRNA gene. It acts as a retrograde signal from mitochondria to the nucleus, activating AMPK (the cellular energy sensor) and promoting metabolic homeostasis. MOTS-c enhances glucose uptake independent of insulin, promotes fatty acid oxidation, and improves exercise capacity. In mouse studies, MOTS-c administration reversed age-related metabolic decline and improved physical performance in old animals to near-youthful levels. NMN (Nicotinamide Mononucleotide) is a direct precursor to NAD+, the essential coenzyme for mitochondrial function, DNA repair (via sirtuins and PARPs), and hundreds of metabolic reactions. NAD+ levels decline approximately 50% between ages 40-60, contributing to mitochondrial dysfunction, impaired DNA repair, and metabolic dysregulation. While NMN is technically a supplement rather than a peptide, its inclusion in this stack reflects the reality that mitochondrial restoration requires adequate NAD+ substrate alongside structural (SS-31) and signaling (MOTS-c) interventions. This is an experimental cutting-edge protocol targeting the fundamental bioenergetic decline of aging.